HC Wainwright Has Positive Outlook for AXSM FY2025 Earnings

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – Research analysts at HC Wainwright upped their FY2025 EPS estimates for Axsome Therapeutics in a research note issued to investors on Tuesday, January 20th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings of ($3.31) per share for the year, up from their prior forecast of ($3.49). HC Wainwright currently has a “Buy” rating and a $260.00 price target on the stock. The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($2.79) per share. HC Wainwright also issued estimates for Axsome Therapeutics’ Q4 2025 earnings at ($0.34) EPS, Q1 2026 earnings at ($0.13) EPS, Q2 2026 earnings at $0.51 EPS and Q3 2026 earnings at $1.46 EPS.

Axsome Therapeutics (NASDAQ:AXSM) last posted its quarterly earnings data on Monday, November 3rd. The company reported ($0.94) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.12). The company had revenue of $170.99 million during the quarter, compared to the consensus estimate of $162.96 million. Axsome Therapeutics had a negative net margin of 40.90% and a negative return on equity of 277.31%. The company’s revenue was up 63.2% compared to the same quarter last year.

Several other research firms have also commented on AXSM. Robert W. Baird set a $209.00 target price on shares of Axsome Therapeutics in a research note on Tuesday, January 13th. Oppenheimer reaffirmed an “outperform” rating and issued a $220.00 price target on shares of Axsome Therapeutics in a report on Wednesday, December 31st. Weiss Ratings reissued a “sell (d-)” rating on shares of Axsome Therapeutics in a research note on Wednesday, October 8th. Needham & Company LLC reaffirmed a “buy” rating and set a $225.00 target price on shares of Axsome Therapeutics in a research report on Monday, January 5th. Finally, Guggenheim reaffirmed a “buy” rating and set a $205.00 target price on shares of Axsome Therapeutics in a report on Friday, January 2nd. Nineteen analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, Axsome Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $203.17.

Axsome Therapeutics Price Performance

Shares of Axsome Therapeutics stock opened at $186.98 on Thursday. Axsome Therapeutics has a 52 week low of $86.99 and a 52 week high of $191.50. The company has a current ratio of 1.57, a quick ratio of 1.50 and a debt-to-equity ratio of 1.66. The stock has a market cap of $9.43 billion, a PE ratio of -40.04, a price-to-earnings-growth ratio of 9.97 and a beta of 0.44. The company’s 50-day moving average price is $158.47 and its two-hundred day moving average price is $132.55.

Insider Transactions at Axsome Therapeutics

In related news, CEO Herriot Tabuteau sold 91,705 shares of the business’s stock in a transaction that occurred on Monday, November 3rd. The stock was sold at an average price of $132.34, for a total value of $12,136,239.70. Following the completion of the sale, the chief executive officer owned 7,229 shares of the company’s stock, valued at approximately $956,685.86. The trade was a 92.69% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Mark E. Saad sold 37,577 shares of the stock in a transaction that occurred on Wednesday, December 31st. The stock was sold at an average price of $165.18, for a total value of $6,206,968.86. Following the completion of the transaction, the director owned 10,002 shares in the company, valued at $1,652,130.36. This represents a 78.98% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 420,903 shares of company stock worth $63,552,838 in the last 90 days. Corporate insiders own 22.30% of the company’s stock.

Institutional Trading of Axsome Therapeutics

Large investors have recently made changes to their positions in the stock. Franklin Street Advisors Inc. NC bought a new position in shares of Axsome Therapeutics in the fourth quarter valued at approximately $1,826,000. Element Squared LLC acquired a new position in Axsome Therapeutics during the 4th quarter worth $1,476,000. Aberdeen Group plc lifted its position in Axsome Therapeutics by 2.9% during the 4th quarter. Aberdeen Group plc now owns 97,413 shares of the company’s stock worth $17,792,000 after acquiring an additional 2,765 shares during the last quarter. Birch Financial Group LLC bought a new stake in Axsome Therapeutics during the fourth quarter valued at about $200,000. Finally, Pallas Capital Advisors LLC grew its position in shares of Axsome Therapeutics by 11.3% in the fourth quarter. Pallas Capital Advisors LLC now owns 43,909 shares of the company’s stock valued at $8,020,000 after purchasing an additional 4,465 shares during the last quarter. Institutional investors own 81.49% of the company’s stock.

Key Axsome Therapeutics News

Here are the key news stories impacting Axsome Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its FY2026 outlook and key later-quarter forecasts (Q4 2026 EPS to $2.06; FY2026 to $3.91), signaling stronger expected profitability in 2026 and underpinning the firm’s Buy rating and $260 target.
• Positive Sentiment: HC Wainwright upgraded several prior estimates to be less negative for FY2025 and Q4 2025 (FY2025 EPS from -$3.49 to -$3.31; Q4 2025 to -$0.34), which narrows near‑term loss expectations and supports the longer‑term bull case.
• Positive Sentiment: Analyst upgrade and commentary drove momentum: American Banking News highlighted HC Wainwright’s bullish outlook and the stock hit a new 12‑month high amid the upgrade. Article Title Article Title
• Neutral Sentiment: Broader analyst coverage roundup and commentary may be amplifying volatility but not decisively shifting fundamentals (analyst compilation by Benzinga). Article Title
• Neutral Sentiment: Zacks notes recent strong intraday gains but cautions that the momentum may not continue without confirming fundamentals — a reminder that short‑term moves can reverse. Article Title
• Negative Sentiment: HC Wainwright trimmed near‑term EPS for Q2 and Q3 2026 (Q2: from $0.65 to $0.51; Q3: from $1.50 to $1.46), which likely pressured the stock intra‑day as investors digest mixed timing of earnings strength.
• Negative Sentiment: Consensus still reflects overall negative full‑year EPS expectations (current consensus ~ -$2.79), reinforcing that the company remains unprofitable on a near‑term basis despite revenue growth.

About Axsome Therapeutics

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.